Associate Professor of Oncology, Associate Professor of Medicine, Assistant Professor of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine; Associate Director for Clinical Practice
Oncology
Dr. John H. Fetting III, MD
John H. Fetting III works in the field of Oncology. He went to medical school at Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a top medical college. Johns Hopkins University School of Medicine is ranked 3 in research and 29 in primary care medicine He has 2 awards "CMS Meaningful Use Stage 1 Certification" and "Top MD". John H. Fetting III, MD is a published MD. He has 57 papers published. The most current publication "Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Interg..." He accepts Medicare payments and is listed with Medicare.gov.
Publications
- TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative Systemic therapy in human epidermal growth factor receptor 2-negative primary operab...
- Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor-Positive Breast Cancer...
- A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer.
- Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast Cancer.
- Survival in patients with metastatic recurrent breast Cancer after adjuvant chemotherapy: Little evidence of improvement over the past 30 years.
- GATA3 expression in Breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.
- Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast Cancer.
- Androgen receptor expression is usually maintained in initial surgically resected breast Cancer metastases but is often lost in end-stage metastases found at autopsy.
- A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast Cancer.
- MYC gene amplification is often acquired in lethal distant breast Cancer metastases of unamplified primary tumors.
- Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole.
- Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive ...
- Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting Breast tumor vaccine: a che...
- African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast Cancer suffer worse outcomes compared with white women.
- Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast Cancer.
- Pulling the trigger.
- A Phase II study of the polyamine Analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast can...
- Clonidine for anticipatory nausea and vomiting: a pilot study examining dose-toxicity relationships and potential for further study.
- Weight gain in patients with breast Cancer receiving adjuvant treatment as a function of restraint, disinhibition, and hunger.
- An efficient method for psychosocial screening of Cancer patients.
- Psychosocial aspects of breast Cancer.
- Psychosocial and other supportive aspects of breast Cancer care.
- Anticipatory nausea and vomiting: does it remain a significant clinical problem?
- Anticipatory nausea and vomiting in an ambulatory medical oncology population.
- The emotional impact of caring for the chronically ill.
- The course of nausea and vomiting after high-dose cyclophosphamide.
- A stopping rule for standard chemotherapy for metastatic breast Cancer: lessons from a survey of Maryland medical oncologists.
- Effects of outcome framing on treatment decisions in the real world: impact of framing on adjuvant breast Cancer decisions.
- Evaluating quality and quantity of life in breast Cancer adjuvant trials.
- Factors affecting treatment decisions for a life-threatening illness: the case of medical treatment of breast Cancer.
- Tastes associated with parenteral chemotherapy for breast Cancer.
- Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for Breast carcinoma.
- Offering the option of randomized clinical trials to Cancer patients who overestimate their prognoses with standard therapies.
- Quality of life and quality adjusted survival for breast Cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG).
- Noradrenergic activity in anticipatory nausea.
- Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Cl...
- The effect of aging on the utilization of chemotherapy for metastatic breast Cancer: a population-based study.
- A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast Cancer.
- Doctor-patient communication about breast Cancer adjuvant therapy.
- Phase II trial of menogaril as initial chemotherapy for metastatic breast Cancer.
- Prevalence of menopausal symptoms among women with a history of breast Cancer and attitudes toward estrogen replacement therapy.
- Autologous graft-versus-host disease induction in advanced breast Cancer: role of peripheral blood progenitor cells.
- A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast Cancer.
- Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk Breast carcinoma.
- Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast Cancer.
- Effect of patients' expectations of benefit with standard breast Cancer adjuvant chemotherapy on participation in a randomized clinical trial: a clinical vignette study.
- Sixteen week dose intense chemotherapy for inoperable, locally advanced breast Cancer.
- Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast Cancer: an Interg...
- A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast Cancer vaccine given in a specifically timed sequence with immuno...
- Heterogeneity of breast Cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases.
- Severe prolonged cholestatic hepatitis caused by exemestane.
- Comparison of breast Cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast Cancer.
- Can you cure him, for the baby's sake?
- Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast Cancer.
- A phase I toxicity and feasibility trial of sequential dose-dense inDuction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consoli...
- Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast Cancer.
Schools
Johns Hopkins University School Of Medicine
Johns Hopkins
Massachusetts General Hospital
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Anxiety
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Choice Advantage
- Blue Choice Network POS
- Blue Preferred PPO
- CareFirst Maryland POS
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- Coventry Health Care of Delaware PPO
- EBS-RMSCO
- Emblem Health
- First Health (Coventry Health Care) PPO
- Geisinger Health Plan
- Humana
- Kaiser Permanente
- MedHealthInsurance
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Tricare
- Choice Plus POS
- Navigate HMO
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
- Top MD
Education
-
Massachusetts General Hospital -
Johns Hopkins University -
Johns Hopkins University School of Medicine
Hospital
-
Johns Hopkins Hospital -
Johns Hopkins Bayview Medical Center
Helpful Reviews
Similar Doctors
|
Judy L. Hetherington, CRNP
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie R. Brahmer, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Arthur A. Serpick, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Myo M. Thant, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mario A. Eisenberger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Deborah K. Armstrong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Judy Hetherington, MD |
|
|
Dr. Seamus Oreilly, MD |
|
|
Dr. Michael H. Brave, MD |